Hikma Pharmaceuticals PLC (LON:HIK) Insider Said Darwazah Sells 13,863 Shares

Hikma Pharmaceuticals PLC (LON:HIK) insider Said Darwazah sold 13,863 shares of the company’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of GBX 2,138 ($28.90), for a total transaction of £296,390.94 ($400,690.74).

Hikma Pharmaceuticals Trading Down 0.8%

LON HIK opened at GBX 2,131.69 ($28.82) on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The company has a fifty day simple moving average of GBX 1,969.65 and a two-hundred day simple moving average of GBX 2,040.33. Hikma Pharmaceuticals PLC has a 12-month low of GBX 1,751 ($23.67) and a 12-month high of GBX 2,360 ($31.90). The stock has a market cap of £5.91 billion, a P/E ratio of 20.92, a P/E/G ratio of 2.38 and a beta of 0.41.

Wall Street Analysts Forecast Growth

HIK has been the topic of a number of research analyst reports. JPMorgan Chase & Co. restated an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Friday, March 7th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 2,560 ($34.61) price target on shares of Hikma Pharmaceuticals in a research report on Monday, March 10th.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.